Cool! I want it with Actinium as well!! 😄
A novel radiopharmaceutical, 177Lu rhPSMA-10.1, has shown promising results in treating metastatic castration-resistant prostate cancer (mCRPC). A Phase 1/2 trial demonstrated high precision in targeting tumors while minimizing damage to healthy tissues (as salivary glands).
Additionally, an independent clinical experience at the University Hospital Augsburg showed that four patients treated with 177Lu rhPSMA-10.1 had significant reductions in PSA levels and progression-free survival (PFS) durations of up to 24 months.
One patient achieved a sustained complete response at two years, with no serious treatment-related adverse events, supporting the therapy's safety and efficacy.
Update on Prostate Cancer Vaccines from Previous Posts done 1 year ago
